M. Bagot - Concepedia

Author

M. Bagot

Also Known As

Bagot Martine, M Bagot, M. BAGOT, M. Bagot, M., Bagot, Martine BAGOT, Martine Bagot, Martine. Bagot, N Basset-Seguin, The members of the HSPrognosis Group

914

Publications

19K

Citations

H-Index

144

Concepts

All Affiliations

Hôpital Saint-Louis Inserm Université Paris Cité Assistance Publique – Hôpitaux de Paris Délégation Paris 7

About

M. Bagot is an author at Hôpital Saint-Louis specializing in medicine, dermatology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	84	6.4K
2	Health Sciences	3	3	306
3	Arts	1	1	145
4	Engineering	1	1	49
5	Natural Sciences	1	1	33

M. Bagot

192

Publications

12.8K

Citations

H-Index

Page 1

	Year	Citations
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer Elise A. Olsen, Sean Whittaker, Youn H. Kim, Journal of Clinical Oncology ImmunodeficienciesImmunologyClinical End PointsPathologyDermatology	2011	641
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial Youn H. Kim, M. Bagot, Lauren Pinter‐Brown, The Lancet Oncology Cutaneous T-cell LymphomaLymphoid NeoplasiaMedicinePathologyMogamulizumab Versus Vorinostat	2018	621
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial H. Miles Prince, Youn H. Kim, Reinhard Dummer, The Lancet Hematological MalignancyLymphoid NeoplasiaMedicineClinical TrialsPathology	2017	569
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model Julia Scarisbrick, H. Miles Prince, Maarten H. Vermeer, Journal of Clinical Oncology	2015	407
Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells Amal Nassif, Armand Bensussan, Laurence Boumsell, Journal of Allergy and Clinical Immunology InflammationToxic Epidermal NecrolysisImmunotoxicologyMedicineCutaneous Biology	2004	401
Drug Specific Cytotoxic T-Cells in the Skin Lesions of a Patient with Toxic Epidermal Necrolysis Amal Nassif, Armand Bensussan, Nicolas Bachot, Journal of Investigative Dermatology Toxic Epidermal NecrolysisMedicineCutaneous BiologyImmunologyHistopathology	2002	302
Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis L. Valeyrie‐Allanore, P. Wolkenstein, Laurent Brochard, British Journal of Dermatology Toxic Epidermal NecrolysisImmunodeficienciesStevens-johnson SyndromePathologyPharmacotherapy	2010	268
Prognostic Factors in Primary Cutaneous Large B-Cell Lymphomas: A European Multicenter Study Florent Grange, Marcel W. Bekkenk, Janine Wechsler, Journal of Clinical Oncology	2001	265
European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes Robert Knobler, Pia Moinzadeh, Nicolas Hunzelmann, Journal of the European Academy of Dermatology and Venereology	2017	255
Guidelines on the use of extracorporeal photopheresis Robert Knobler, Gösta Berlin, Piergiacomo Calzavara‐Pinton, Journal of the European Academy of Dermatology and Venereology	2013	217

Page 1